These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 11365623)

  • 1. PIT study produces more questions than answers.
    TreatmentUpdate; 1998 Jul; 10(5):1-2. PubMed ID: 11365623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donating antibodies as a treatment for HIV.
    TreatmentUpdate; 1998 Jul; 10(5):2-3. PubMed ID: 11365624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068.
    Jacobson JM; Pat Bucy R; Spritzler J; Saag MS; Eron JJ; Coombs RW; Wang R; Fox L; Johnson VA; Cu-Uvin S; Cohn SE; Mildvan D; O'Neill D; Janik J; Purdue L; O'Connor DK; Vita CD; Frank I;
    J Infect Dis; 2006 Sep; 194(5):623-32. PubMed ID: 16897661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement of HIV-1 p24 antigen by signal-amplification-boosted ELISA of heat-denatured plasma is a simple and inexpensive alternative to tests for viral RNA.
    Schüpbach J
    AIDS Rev; 2002; 4(2):83-92. PubMed ID: 12152521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticardiolipin antibodies in HIV infection are independently associated with antibodies to the membrane proximal external region of gp41 and with cell-associated HIV DNA and immune activation.
    Martinez V; Diemert MC; Braibant M; Potard V; Charuel JL; Barin F; Costagliola D; Caumes E; Clauvel JP; Autran B; Musset L;
    Clin Infect Dis; 2009 Jan; 48(1):123-32. PubMed ID: 19035778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 IgA specific serum antibodies and disease progression during HIV-1 infection.
    Margalith M; Levy E; Rinaldo CR; Detels R; Phair J; Kaslow R; Saah AJ; Sarov B
    J Hum Virol; 2001; 4(5):269-77. PubMed ID: 11907384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SPV-30 may offer CD4 increase.
    Posit Aware; 1995; ():7. PubMed ID: 11362383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Viral load test conducive to excluding negative subjects from suspects in HIV antibody detections].
    Hei FX; Zhang QY; Sun WD; Zhang Q; Ye JR; Liu HL; Lu HY
    Zhonghua Yu Fang Yi Xue Za Zhi; 2008 Jan; 42(1):43-6. PubMed ID: 18512327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
    Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO
    West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up.
    Longo O; Tripiciano A; Fiorelli V; Bellino S; Scoglio A; Collacchi B; Alvarez MJ; Francavilla V; Arancio A; Paniccia G; Lazzarin A; Tambussi G; Din CT; Visintini R; Narciso P; Antinori A; D'Offizi G; Giulianelli M; Carta M; Di Carlo A; Palamara G; Giuliani M; Laguardia ME; Monini P; Magnani M; Ensoli F; Ensoli B
    Vaccine; 2009 May; 27(25-26):3306-12. PubMed ID: 19208456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection.
    Fagard C; Oxenius A; Günthard H; Garcia F; Le Braz M; Mestre G; Battegay M; Furrer H; Vernazza P; Bernasconi E; Telenti A; Weber R; Leduc D; Yerly S; Price D; Dawson SJ; Klimkait T; Perneger TV; McLean A; Clotet B; Gatell JM; Perrin L; Plana M; Phillips R; Hirschel B;
    Arch Intern Med; 2003 May; 163(10):1220-6. PubMed ID: 12767960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial.
    Hurwitz BE; Klaus JR; Llabre MM; Gonzalez A; Lawrence PJ; Maher KJ; Greeson JM; Baum MK; Shor-Posner G; Skyler JS; Schneiderman N
    Arch Intern Med; 2007 Jan; 167(2):148-54. PubMed ID: 17242315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Passive immunization for the treatment of HIV infection.
    Jacobson JM
    Mt Sinai J Med; 1998 Jan; 65(1):22-6. PubMed ID: 9458680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Investigation of anti-R7V antibodies in HIV-infected patients under highly active antiretroviral therapy].
    Ergünay K; Altinbaş A; Calik Başaran N; Unal S; Us D; Karabulut E; Ustaçelebi S
    Mikrobiyol Bul; 2008 Jul; 42(3):413-9. PubMed ID: 18822884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Model for competition from self during passive immunization, with application to broadly neutralizing antibodies for HIV.
    Ali Tabei SM; Li Y; Weigert M; Dinner AR
    Vaccine; 2012 Jan; 30(3):607-13. PubMed ID: 22119591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4+ T cell-dependent reduction in hepatitis C virus-specific humoral immune responses after HIV infection.
    Netski DM; Mosbruger T; Astemborski J; Mehta SH; Thomas DL; Cox AL
    J Infect Dis; 2007 Mar; 195(6):857-63. PubMed ID: 17299716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of diethylcarbamazine on HIV load, CD4%, and CD4/CD8 ratio in HIV-infected adult Tanzanians with or without lymphatic filariasis: randomized double-blind and placebo-controlled cross-over trial.
    Nielsen NO; Simonsen PE; Dalgaard P; Krarup H; Magnussen P; Magesa S; Friis H
    Am J Trop Med Hyg; 2007 Sep; 77(3):507-13. PubMed ID: 17827369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.